Skip to main content

Table 3 Associations between the three groups of patients and biomarkers: prodromal dementia with Lewy bodies group (pro-DLB), group with one core symptom (1S group), group without any core DLB symptoms (NS group)

From: Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort

  1S (vs NS) Pro-DLB (vs NS) P-value
OR [IC95%] OR [IC95%]
ABeta42 abnormal (vs normal) 0.99 [0.36; 2.71] 0.25 [0.04; 1.61] 0.33
T-Tau abnormal (vs normal) 0.36 [0.15; 0.91] 0.40 [0.10; 1.66] 0.067
P-Tau abnormal (vs normal) 0.48 [0.21; 1.08] 0.48 [0.14; 1.64] 0.15
ABeta42/40 abnormal (vs normal) 0.66 [0.25; 1.71] 0.86 [0.20; 3.66] 0.69
Amyloid PET + (vs −) 0.88 [0.40; 1.93] 1.13 [0.36; 3.58] 0.91
  Betaa [IC95%] Betaa [IC95%] P-value
Intracranial volume, cm3 − 5.55 [− 22.4;11.28] − 14.3 [− 35.6; 7.01] 0.41
BPF, % − 1.11 [− 1.85; − 0.36] − 0.42 [− 1.36; 0.53] 0.015
Hippocampal volume, mm3 0.02 [− 0.14; 0.17] − 0.09 [− 0.29; 0.11] 0.61
Mean cortical thickness, mm − 0.01 [− 0.02; 0.01] − 0.01 [− 0.03; 0.01] 0.36
ROI cortical thickness ROI, mm − 0.01 [− 0.03; 0.01] − 0.02 [− 0.05; 0.01] 0.26
WMH volume, log (mm3) 0.15 [ 0.01; 0.29] 0.11 [− 0.07; 0.29] 0.094
SUVR PET-FDG 0.02 [− 0.02; 0.06] − 0.02 [− 0.07; 0.03] 0.43
SUVR PET-FDG for disease specific ROI − 0.00 [− 0.05; 0.04] − 0.03 [− 0.09; 0.04] 0.68
  1. The models in the table are adjusted for sex, age, education level, ApoE, type of MRI (if MRI measurement), and intracranial volume (if MRI and except for intracranial volume and BPF)
  2. Abbreviations: ADNI Alzheimer’s Disease Neuroimaging Initiative, BPF brain parenchymal fraction, FDG fluorodeoxyglucose, PET positron emission tomography, ROI region of interest, WMH white matter hypersignals
  3. aFor a change in 1 unit of the biomarker